Walgreens Acquired: What Private Equity Means for Your Healthcare
Ask about Knowledge at Wharton
Episode Description
Private equity investment in the U.S. healthcare sector has grown significantly over the past decade, peaking in 2021 with $100 billion in deals, though it slowed in 2022–2023 due to economic factors. While private equity can improve efficiency and provide capital and management support, concerns persist around reduced care quality, lack of transparency, and increased healthcare costs. Several states, including Pennsylvania, are now exploring regulatory measures to increase oversight and transparency in private equity healthcare transactions.
In the wake of Walgreens agreeing to be acquired by Sycamore Partners, Atul Gupta, Wharton assistant professor of health care management, joined the Wharton Business Daily podcast to discuss the growing involvement of private equity in the health care sector, its benefits and risks, and the regulatory challenges surrounding transparency and ownership structures.
ABOUT THE PODCAST The Wharton Business Daily podcast features interviews with top business leaders, innovators, and renowned Wharton faculty about the latest news, fascinating trends, and issues impacting both consumers and the business world. Episodes are recorded at the Wharton School.
#Walgreens #PrivateEquity #HealthcareBusiness #HealthcareReform #HealthcarePolicy ----- The Wharton School of the University of Pennsylvania is committed to sharing its intellectual capital through Knowledge at Wharton, the school’s online business analysis journal.
Launched in 1999, Knowledge at Wharton offers free access to:
- Articles, podcasts, and videos highlighting Wharton faculty research and analysis of current business trends - Interviews with book authors from Wharton School Press - In-depth series of curated content like Wharton Executive Education’s Nano Tools for Leaders - A searchable database of more than 10,000 articles covering all aspects of business - A weekly newsletter that delivers Knowledge at Wharton insights directly to your inbox
Visit the Knowledge at Wharton homepage: https://whr.tn/3qUpSBE Subscribe to the Knowledge at Wharton YouTube channel: https://whr.tn/3DEAgAU
Read the full transcriptHide the full transcript
- Dan Loney: Well, you may have recently heard that Walgreens was going to be acquired by private equity firm Sycamore
- Partners. It is not the first time, and probably won't be the last, that we will hear about private equity's involvement in
- the health care sector, as it has been growing significantly in the last many years. To discuss where this takes health
- care right now, we're joined right now by Atul Gupta, who is Assistant Professor of Healthcare Management
- here at the Wharton School. Atul, great to talk to you again. How are you? I'm great. Thank you so much for having me again, Dan.
- Thank you. And again, this latest announcement with Walgreens kind of highlighting the influence or the importance that private
- equity sees in the healthcare sector right now. Tell us about how you view the connection between private equity and
- healthcare at the moment. Yeah. So you know, as you said, private equity has been growing
- its— its investment into healthcare, particularly in the US, over the last decade. If you— if you chart their growth in
- healthcare, it's been growing pretty much every year, year on year, until 2021. That was the peak, when we had about 100
- billion, with a B, dollars of investment in healthcare. But since then, as you know, the interest rate environment has
- turned pretty unfavorable. There's also been this sort of vibe-session, recession sort of concerns. And so since then,
- actually, private equity investments in healthcare have dropped. 2022 and 2023 were actually pretty linear, and the
- early numbers from 2024 suggest that now things are beginning to rev up again. And so, you know, now we have this new deal
- suggesting that 2025 might actually be going back in the same direction of higher deal values.
- So what has private equity, then, brought to health care? So, that's a great question, you know. And honestly, I don't think that
- there's a consensus on that yet. You know, there's— if you look at— if you just look at it conceptually, private equity can
- be a vehicle for great good, because they tend to be more efficient. They tend to bring investments into IT and sort of
- cutting edge management practices. They're obviously very sophisticated in their financial practices. So all of
- that suggests that there could be some good there. But then, on the other hand, because it's such a high-powered financial
- incentive model, and because healthcare markets are so imperfect, if you bring these two forces together, it could
- lead to some negative consequences for patients, for taxpayers. And so there has been some evidence suggesting that
- when private equity gets involved, particularly in healthcare providers— you know, for example, evidence from hospitals
- and nursing homes— they tend to cut back on staff, which can lead to poor quality outcomes for patients. So I would say the
- evidence is pretty mixed. And it sounds like the the issue of transparency is one that
- seems to be a concern by many on the outside. Absolutely, I would say transparency is probably one of
- two most important issues with the involvement of private equity in healthcare. It's— as you know, as you may know, it's
- very difficult to actually track the ownership of these firms. When a private equity invests in a target, it's very difficult to
- figure that out, because they use a very complex structure of ownership. The deal terms are not transparent to outsiders—
- and by outsiders, I mean anybody who's not part— a party to the deal. Because it's a private business model, they don't have
- the same kind of regulatory compliance that publicly-listed firms face. So there are a number of challenges to actually
- tracking the performance of private-equity-owned firms. But it seems like there are states that have concerns about
- the level of growth. Pennsylvania, where we are, being one of them. Tell us— take us through that side of the story.
- Yeah, a number of states are actually considering regulatory action on their own, without waiting for the Feds on— on— on improving— on
- increasing transparency, on— on, actually, not just private equity. So California looked into this. But I think at the
- last minute, Governor Newsom vetoed that bill, which would have actually given the state attorney general more power to
- block healthcare deals by private equity firms. In Pennsylvania, again, the legislature is looking at this
- as well. Here, I think I'm more optimistic that actually there'll be more significant action that will be taken,
- particularly with regards to transparency and how data will be available. Not just on private equity, but also,
- you know, transactions above a certain size. Is the decision process for, then, businesses in healthcare— and
- look, you have big health systems and you have smaller businesses like physical therapists, etc. I mean, I would
- think it can be a relatively simple decision to invite private equity into your business and provide the support
- that maybe some businesses are looking for. Absolutely. I think that for— for small practices,
- physician practices like physical therapists, like you mentioned— I think for them, it— private equity can be a real
- help, because they bring in some of this technological support, management support, access to capital that they lack on their
- own. And actually it can make life easier for the physician. And that's part of the appeal of private equity, particularly for
- young physicians who, you know, don't— there's been a cultural shift in that the newer generation of physicians don't
- actually want to get bogged down in all that goes into running your own practice. That being said, you know, I've spoken with
- a number of physicians. And sort of, you know, reading about this in the academic literature, you know, physicians are now
- beginning to get worried that with all of this investment and the good, there's also some concerning things that come in,
- which is that private equity firms sometimes start controlling your treatment decisions. Or, you know, they
- may influence you, you know, towards doing certain kinds of procedures. The other thing that doesn't directly affect
- physicians, but affects society at large, is that private equity firms, when they acquire these physician practices, they
- renegotiate the prices with private insurers. And they try to get higher prices. And what that means for patients and
- customers in general is that the cost of your healthcare premiums goes up, whereas the quality of the service may remain the same.
- Well, but we don't have definitive data that the care has been impacted to this point, right?
- No, not on the physician practice side. In fact, I am quite optimistic that private equity involvement with physician
- practices and small businesses in general can actually improve their efficiency, and hopefully some of those efficiencies can
- then get passed through to insurers in the form of lower costs. And this all coming at a time where we're seeing a big change
- in health care anyway, with the move to digital. Obviously, when you look at labor, health care has been a big supporter of the
- labor markets over the last what, decade or so? Yeah, no, absolutely. Healthcare is now— if not the largest, it's
- probably one of the top two or three largest sectors in terms of employment in the US. And as we all know, healthcare is
- recession-proof, or at least perceived to be recession-proof. We'll find out. And— and so that's, you know, part of the
- appeal of private equity, also, for, you know, why they're interested in health care, is because they think that health
- care will continue to grow. But it sounds like this is an area to watch, when you talk
- about the investment that PE is making in health care, and what the government at the state or local level might be looking to—
- to draw out of them in the months and years ahead. Yeah, absolutely. I think we should all watch this space very
- carefully. Governments are going to seek more transparency. I would encourage them to also think about aligning the
- incentives of private equity firms with those of patients and taxpayers in the form of— you know, perhaps, you know, in the
- use of value-based payments, which link their performance on quality and spending to their payments. So I think you'll see—
- you'll start to see some movement on that. And then, of course, you know, if private equity does get back to the good
- old days, then you'll start seeing a lot more deals, particularly on physician practices.
- Atul, great to talk to you. Thanks for your insight. All the best. Thank you so much.
- Thank you. Atul Gupta, who's Assistant Professor of Healthcare Management here at the Wharton School.
Brief Summary
Atul Gupta discusses Walgreens' acquisition by Sycamore Partners and private equity's impact on healthcare transparency and quality.
Key points
- Private Equity's Growing Influence. Private equity's investment in healthcare has surged, peaking at $100 billion in 2021.
- Concerns Over Transparency. The complexity of private equity ownership structures raises transparency issues in healthcare.
- Potential Risks for Patients. Atul Gupta highlights the mixed evidence regarding private equity's impact on patient care quality.
Episode highlights
- Private Equity's Growing InfluencePrivate equity's investment in healthcare has surged, peaking at $100 billion in 2021.“Private equity has been growing its investment into healthcare, particularly in the US.”0:47Apr 6, 2025
- Concerns Over TransparencyThe complexity of private equity ownership structures raises transparency issues in healthcare.“Transparency is probably one of two most important issues with private equity in healthcare.”2:57Apr 6, 2025
- Potential Risks for PatientsAtul Gupta highlights the mixed evidence regarding private equity's impact on patient care quality.“Private equity firms sometimes start controlling your treatment decisions.”5:48Apr 6, 2025





